anti primary her2  (Cell Signaling Technology Inc)


Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    Cell Signaling Technology Inc anti primary her2
    Anti Primary Her2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti primary her2/product/Cell Signaling Technology Inc
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti primary her2 - by Bioz Stars, 2024-06
    86/100 stars

    Images

    anti primary her2  (Cell Signaling Technology Inc)


    Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    Cell Signaling Technology Inc anti primary her2
    Anti Primary Her2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti primary her2/product/Cell Signaling Technology Inc
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti primary her2 - by Bioz Stars, 2024-06
    86/100 stars

    Images

    primary antibodies anti her2  (Cell Signaling Technology Inc)


    Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    Cell Signaling Technology Inc primary antibodies anti her2
    Primary Antibodies Anti Her2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary antibodies anti her2/product/Cell Signaling Technology Inc
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    primary antibodies anti her2 - by Bioz Stars, 2024-06
    86/100 stars

    Images

    primary antibodies against her2  (Cell Signaling Technology Inc)


    Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    Cell Signaling Technology Inc primary antibodies against her2
    Aptamer selection with cell-SELEX method. A total of 15 selection rounds were applied to enrich DNA aptamer sequences that bind to <t>HER2-overexpressing</t> live breast cancer cell lines SK-BR-3 and MDA-MB-453. MDA-MB-231 cells were used for negative selection.
    Primary Antibodies Against Her2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary antibodies against her2/product/Cell Signaling Technology Inc
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    primary antibodies against her2 - by Bioz Stars, 2024-06
    86/100 stars

    Images

    1) Product Images from "Theranostic potential of a novel aptamer specifically targeting HER2 in breast cancer cells"

    Article Title: Theranostic potential of a novel aptamer specifically targeting HER2 in breast cancer cells

    Journal: Turkish Journal of Biology

    doi: 10.55730/1300-0152.2680

    Aptamer selection with cell-SELEX method. A total of 15 selection rounds were applied to enrich DNA aptamer sequences that bind to HER2-overexpressing live breast cancer cell lines SK-BR-3 and MDA-MB-453. MDA-MB-231 cells were used for negative selection.
    Figure Legend Snippet: Aptamer selection with cell-SELEX method. A total of 15 selection rounds were applied to enrich DNA aptamer sequences that bind to HER2-overexpressing live breast cancer cell lines SK-BR-3 and MDA-MB-453. MDA-MB-231 cells were used for negative selection.

    Techniques Used: Selection

    Expression levels of HER2, HER3, and EGFR on breast cancer cells. Receptor protein levels in MDA-MB-453, SK-BR-3, and MDA-MB-231 cells were detected by on-cell western method using anti-HER2, anti-HER3, and anti-EGFR primary antibodies, then antirabbit 800 (green) conjugated secondary antibody and CellTag 700 (red) stain for normalization of cell number. The plates were scanned in the 800 or 700 nm channels of LI-COR Odyssey Infrared Imaging System.
    Figure Legend Snippet: Expression levels of HER2, HER3, and EGFR on breast cancer cells. Receptor protein levels in MDA-MB-453, SK-BR-3, and MDA-MB-231 cells were detected by on-cell western method using anti-HER2, anti-HER3, and anti-EGFR primary antibodies, then antirabbit 800 (green) conjugated secondary antibody and CellTag 700 (red) stain for normalization of cell number. The plates were scanned in the 800 or 700 nm channels of LI-COR Odyssey Infrared Imaging System.

    Techniques Used: Expressing, Western Blot, Staining, Imaging

    Concentration-dependent binding of HMAP7 to HER2 overexpressing breast cancer cells. (A) MDA-MB-453 and SK-BR-3 cells were incubated with increasing concentrations of IRD800-labelled HMAP7 (green) for 1 h. Subsequently, the fluorescence intensities were detected by Infrared Imaging System and used to calculate the dissociation constant Kd value of HMAP7. Anti-HER2 primary and 680RD–labeled (red) secondary antibodies were used to detect HER2 levels. (B) The graph of HMAP7-IRD 800 concentration against fluorescence intensity was plotted. Error bars were calculated as standard error.
    Figure Legend Snippet: Concentration-dependent binding of HMAP7 to HER2 overexpressing breast cancer cells. (A) MDA-MB-453 and SK-BR-3 cells were incubated with increasing concentrations of IRD800-labelled HMAP7 (green) for 1 h. Subsequently, the fluorescence intensities were detected by Infrared Imaging System and used to calculate the dissociation constant Kd value of HMAP7. Anti-HER2 primary and 680RD–labeled (red) secondary antibodies were used to detect HER2 levels. (B) The graph of HMAP7-IRD 800 concentration against fluorescence intensity was plotted. Error bars were calculated as standard error.

    Techniques Used: Concentration Assay, Binding Assay, Incubation, Fluorescence, Imaging, Labeling

    The comparison of the receptor-based binding specificities of selected (HMAP7 and M9) and reported (2-2t) aptamers. (A) HER2-overexpressing MDA-MB-453 and SK-BR-3, and HER2-negative MDA-MB-231 cells were incubated with IRD 800-labeled (green) HMAP7, M9 or 2-2t aptamers for 1 h. Subsequently, CellTag 700 (red) applied on-cell western assay. Mean fluorescence intensities were detected by infrared imaging and plotted with standard error as shown (B) .
    Figure Legend Snippet: The comparison of the receptor-based binding specificities of selected (HMAP7 and M9) and reported (2-2t) aptamers. (A) HER2-overexpressing MDA-MB-453 and SK-BR-3, and HER2-negative MDA-MB-231 cells were incubated with IRD 800-labeled (green) HMAP7, M9 or 2-2t aptamers for 1 h. Subsequently, CellTag 700 (red) applied on-cell western assay. Mean fluorescence intensities were detected by infrared imaging and plotted with standard error as shown (B) .

    Techniques Used: Comparison, Binding Assay, Incubation, Labeling, Western Blot, Fluorescence, Imaging

    (A) NIR-labeled capture immunoassay for targeted optical imaging. HMAP7-IRD800-treated (green) or IRD800-treated (control) MDA-MB-453 cell lysates were incubated with the streptavidin-coated 96-well plate pretreated with biotinylated anti-HER2-affibody. Then anti-HER2 primary antibody was used and detected with antirabbit 680RD secondary antibody (red) and scanned in the 800 nm and 700 nm channels of LI-COR Odyssey Infrared Imaging System. (B) Schematic diagram of NIR-labeled capture immunoassay.
    Figure Legend Snippet: (A) NIR-labeled capture immunoassay for targeted optical imaging. HMAP7-IRD800-treated (green) or IRD800-treated (control) MDA-MB-453 cell lysates were incubated with the streptavidin-coated 96-well plate pretreated with biotinylated anti-HER2-affibody. Then anti-HER2 primary antibody was used and detected with antirabbit 680RD secondary antibody (red) and scanned in the 800 nm and 700 nm channels of LI-COR Odyssey Infrared Imaging System. (B) Schematic diagram of NIR-labeled capture immunoassay.

    Techniques Used: Labeling, Optical Imaging, Incubation, Imaging

    her2 primary antibody  (Cell Signaling Technology Inc)


    Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    Cell Signaling Technology Inc her2 primary antibody
    Her2 Primary Antibody, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/her2 primary antibody/product/Cell Signaling Technology Inc
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    her2 primary antibody - by Bioz Stars, 2024-06
    86/100 stars

    Images

    her2 primary antibody  (Cell Signaling Technology Inc)


    Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    Cell Signaling Technology Inc her2 primary antibody
    Confocal images of BP-PEG-FITC-MTO (a) and BP-PEG-FITC-MTO-Tmab (b) cocultured with <t>HER2-positive</t> SK-BR-3 cells for 1 h (scale bar = 100 μm).
    Her2 Primary Antibody, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/her2 primary antibody/product/Cell Signaling Technology Inc
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    her2 primary antibody - by Bioz Stars, 2024-06
    86/100 stars

    Images

    1) Product Images from "HER2-targeting two-dimensional black phosphorus as a nanoplatform for chemo-photothermal therapy in breast cancer"

    Article Title: HER2-targeting two-dimensional black phosphorus as a nanoplatform for chemo-photothermal therapy in breast cancer

    Journal: Materials Today Bio

    doi: 10.1016/j.mtbio.2023.100812

    Confocal images of BP-PEG-FITC-MTO (a) and BP-PEG-FITC-MTO-Tmab (b) cocultured with HER2-positive SK-BR-3 cells for 1 h (scale bar = 100 μm).
    Figure Legend Snippet: Confocal images of BP-PEG-FITC-MTO (a) and BP-PEG-FITC-MTO-Tmab (b) cocultured with HER2-positive SK-BR-3 cells for 1 h (scale bar = 100 μm).

    Techniques Used:

    (a) Immunofluorescence staining of HER-2 (green signal) and DAPI (blue signal) in 4T1 control cells and HER-2 overexpressing 4T1-Her2 cells, scale bars = 20 μm. (b–c ) Representative fluorescent images of HER-2 positive 4T1-Her2 tumors (left, n = 3) and HER-2 negative 4T1 tumors (right, n = 3) visualized from IVIS Kinetic 24 h after intravenous injection with BP-ICG-Tmab. The ICG fluorescence intensity was enriched in 4T1-Her2 tumors than 4T1 group (*p < 0.05). (d–e) Comparable pattern of tumors ICG fluorescence between 4T1-Her2 (upper panel) and 4T1 (lower panel) tumors ex vivo (*p < 0.05). (f–g) The in vivo thermographic surveillance of photothermal heating in mice bearing 4T1-Her2 tumors after intravenous injection with/without Tmab nanoparticles (BP, BP-PEG-MTO, BP-PEG-Tmab, BP-PEG-MTO-Tmab; n = 5 for each group) and irradiation for 10 min using an 808 nm laser at 1.0 W/cm 2 .
    Figure Legend Snippet: (a) Immunofluorescence staining of HER-2 (green signal) and DAPI (blue signal) in 4T1 control cells and HER-2 overexpressing 4T1-Her2 cells, scale bars = 20 μm. (b–c ) Representative fluorescent images of HER-2 positive 4T1-Her2 tumors (left, n = 3) and HER-2 negative 4T1 tumors (right, n = 3) visualized from IVIS Kinetic 24 h after intravenous injection with BP-ICG-Tmab. The ICG fluorescence intensity was enriched in 4T1-Her2 tumors than 4T1 group (*p < 0.05). (d–e) Comparable pattern of tumors ICG fluorescence between 4T1-Her2 (upper panel) and 4T1 (lower panel) tumors ex vivo (*p < 0.05). (f–g) The in vivo thermographic surveillance of photothermal heating in mice bearing 4T1-Her2 tumors after intravenous injection with/without Tmab nanoparticles (BP, BP-PEG-MTO, BP-PEG-Tmab, BP-PEG-MTO-Tmab; n = 5 for each group) and irradiation for 10 min using an 808 nm laser at 1.0 W/cm 2 .

    Techniques Used: Immunofluorescence, Staining, Injection, Fluorescence, Ex Vivo, In Vivo, Irradiation

    (a) Schematic representation of 4T1-Her2 tumor ectopic implantation model and phototherapy in mice. (b) Variation in tumor volume of mice after intravenous injection of PBS, BP, BP-PEG-MTO, BP-PEG-Tmab, BP-PEG-MTO-Tmab with/without 808 nm laser irradiation (1.0 W/cm 2 ) for 10 min at an initial stage (n = 5 per group, ***p < 0.001, ns = not significant). (c–d) Representative images of tumor volume and quantified data of tumor mass (**p < 0.01, ***p < 0.001). (e) Representative images of H&E staining (scale bars = 100 μm), immunohistochemical staining for Ki67 (scale bars = 100 μm), and TUNEL staining (scale bars = 50 μm) in tumor tissue.
    Figure Legend Snippet: (a) Schematic representation of 4T1-Her2 tumor ectopic implantation model and phototherapy in mice. (b) Variation in tumor volume of mice after intravenous injection of PBS, BP, BP-PEG-MTO, BP-PEG-Tmab, BP-PEG-MTO-Tmab with/without 808 nm laser irradiation (1.0 W/cm 2 ) for 10 min at an initial stage (n = 5 per group, ***p < 0.001, ns = not significant). (c–d) Representative images of tumor volume and quantified data of tumor mass (**p < 0.01, ***p < 0.001). (e) Representative images of H&E staining (scale bars = 100 μm), immunohistochemical staining for Ki67 (scale bars = 100 μm), and TUNEL staining (scale bars = 50 μm) in tumor tissue.

    Techniques Used: Injection, Irradiation, Staining, Immunohistochemistry, TUNEL Assay

    (a) Representative images of H&E staining of organs (heart, kidney, liver, lung, and spleen) tissue in the xenograft models after different treatments. (b) Schematic model for BP-PEG-MTO-Tmab in targeted PTT in HER2-positive breast cancer.
    Figure Legend Snippet: (a) Representative images of H&E staining of organs (heart, kidney, liver, lung, and spleen) tissue in the xenograft models after different treatments. (b) Schematic model for BP-PEG-MTO-Tmab in targeted PTT in HER2-positive breast cancer.

    Techniques Used: Staining

    her2 primary antibody 29d8  (Cell Signaling Technology Inc)


    Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    Cell Signaling Technology Inc her2 primary antibody 29d8
    Her2 Primary Antibody 29d8, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/her2 primary antibody 29d8/product/Cell Signaling Technology Inc
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    her2 primary antibody 29d8 - by Bioz Stars, 2024-06
    86/100 stars

    Images

    her2 primary antibody 29d8  (Cell Signaling Technology Inc)


    Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    Cell Signaling Technology Inc her2 primary antibody 29d8
    Her2 Primary Antibody 29d8, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/her2 primary antibody 29d8/product/Cell Signaling Technology Inc
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    her2 primary antibody 29d8 - by Bioz Stars, 2024-06
    86/100 stars

    Images

    primary anti her2  (Cell Signaling Technology Inc)


    Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    Cell Signaling Technology Inc primary anti her2
    Primary Anti Her2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary anti her2/product/Cell Signaling Technology Inc
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    primary anti her2 - by Bioz Stars, 2024-06
    86/100 stars

    Images

    anti erbb2 monoclonal primary antibody  (Cell Signaling Technology Inc)


    Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 96

    Structured Review

    Cell Signaling Technology Inc anti erbb2 monoclonal primary antibody
    Clinicopathological characteristics of HAS and stage-matched non-HAS patients
    Anti Erbb2 Monoclonal Primary Antibody, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti erbb2 monoclonal primary antibody/product/Cell Signaling Technology Inc
    Average 96 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti erbb2 monoclonal primary antibody - by Bioz Stars, 2024-06
    96/100 stars

    Images

    1) Product Images from "Integrative analysis reveals a clinicogenomic landscape associated with liver metastasis and poor prognosis in hepatoid adenocarcinoma of the stomach"

    Article Title: Integrative analysis reveals a clinicogenomic landscape associated with liver metastasis and poor prognosis in hepatoid adenocarcinoma of the stomach

    Journal: International Journal of Biological Sciences

    doi: 10.7150/ijbs.71449

    Clinicopathological characteristics of HAS and stage-matched non-HAS patients
    Figure Legend Snippet: Clinicopathological characteristics of HAS and stage-matched non-HAS patients

    Techniques Used:

    Potential targets and therapy for HAS. (A) Frequently altered genomic targets in HAS compared with non-HAS. (B) Comparison of ERBB2 expression between HAS and non-HAS. (C) Comparison of TMB between HAS and non-HAS. (D) Assessment of serum AFP and CEA levels in HAS patients before and after treatment. Three HAS patients received anti-ERBB2 therapy and five HAS patients received anti-PD-1 therapy. The line charts represent serum AFP/CEA level and histograms represent the CP of serum AFP/CEA level; details are shown as follows: CP (%) = (serum AFP or CEA levels before treatment - serum AFP or CEA levels after treatment) / serum AFP or CEA levels before treatment *100%. The values of 20 ng/mL and 5 ng/mL are defined as the serum AFP and CEA levels threshold, respectively. For each patient with elevated AFP/CEA level before treatment, 65% was defined as the cutoff for response to anti-ERBB2/anti-PD-1 therapy. Blue and red represent response and no response at the serum tumor biomarker levels, respectively. Grey means that this evaluation criterion is inapplicable for a patient with a normal AFP/CEA level before treatment. (E) Representative CT images of abdomen showing tumor lesions of two patients before and after treatment; one received anti-ERBB2 therapy and the other received anti-PD-1 therapy. The dotted line represents the metastatic liver lesion, and the arrow represents the primary gastric lesion. IHC, immunohistochemistry; AFP, alpha-fetoprotein; CEA, carcinoembryonic antigen; CP, change percent; Pt, patient.
    Figure Legend Snippet: Potential targets and therapy for HAS. (A) Frequently altered genomic targets in HAS compared with non-HAS. (B) Comparison of ERBB2 expression between HAS and non-HAS. (C) Comparison of TMB between HAS and non-HAS. (D) Assessment of serum AFP and CEA levels in HAS patients before and after treatment. Three HAS patients received anti-ERBB2 therapy and five HAS patients received anti-PD-1 therapy. The line charts represent serum AFP/CEA level and histograms represent the CP of serum AFP/CEA level; details are shown as follows: CP (%) = (serum AFP or CEA levels before treatment - serum AFP or CEA levels after treatment) / serum AFP or CEA levels before treatment *100%. The values of 20 ng/mL and 5 ng/mL are defined as the serum AFP and CEA levels threshold, respectively. For each patient with elevated AFP/CEA level before treatment, 65% was defined as the cutoff for response to anti-ERBB2/anti-PD-1 therapy. Blue and red represent response and no response at the serum tumor biomarker levels, respectively. Grey means that this evaluation criterion is inapplicable for a patient with a normal AFP/CEA level before treatment. (E) Representative CT images of abdomen showing tumor lesions of two patients before and after treatment; one received anti-ERBB2 therapy and the other received anti-PD-1 therapy. The dotted line represents the metastatic liver lesion, and the arrow represents the primary gastric lesion. IHC, immunohistochemistry; AFP, alpha-fetoprotein; CEA, carcinoembryonic antigen; CP, change percent; Pt, patient.

    Techniques Used: Expressing, Biomarker Assay, Immunohistochemistry

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86
    Cell Signaling Technology Inc anti primary her2
    Anti Primary Her2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti primary her2/product/Cell Signaling Technology Inc
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti primary her2 - by Bioz Stars, 2024-06
    86/100 stars
      Buy from Supplier

    86
    Cell Signaling Technology Inc primary antibodies anti her2
    Primary Antibodies Anti Her2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary antibodies anti her2/product/Cell Signaling Technology Inc
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    primary antibodies anti her2 - by Bioz Stars, 2024-06
    86/100 stars
      Buy from Supplier

    86
    Cell Signaling Technology Inc primary antibodies against her2
    Aptamer selection with cell-SELEX method. A total of 15 selection rounds were applied to enrich DNA aptamer sequences that bind to <t>HER2-overexpressing</t> live breast cancer cell lines SK-BR-3 and MDA-MB-453. MDA-MB-231 cells were used for negative selection.
    Primary Antibodies Against Her2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary antibodies against her2/product/Cell Signaling Technology Inc
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    primary antibodies against her2 - by Bioz Stars, 2024-06
    86/100 stars
      Buy from Supplier

    86
    Cell Signaling Technology Inc her2 primary antibody
    Aptamer selection with cell-SELEX method. A total of 15 selection rounds were applied to enrich DNA aptamer sequences that bind to <t>HER2-overexpressing</t> live breast cancer cell lines SK-BR-3 and MDA-MB-453. MDA-MB-231 cells were used for negative selection.
    Her2 Primary Antibody, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/her2 primary antibody/product/Cell Signaling Technology Inc
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    her2 primary antibody - by Bioz Stars, 2024-06
    86/100 stars
      Buy from Supplier

    86
    Cell Signaling Technology Inc her2 primary antibody 29d8
    Aptamer selection with cell-SELEX method. A total of 15 selection rounds were applied to enrich DNA aptamer sequences that bind to <t>HER2-overexpressing</t> live breast cancer cell lines SK-BR-3 and MDA-MB-453. MDA-MB-231 cells were used for negative selection.
    Her2 Primary Antibody 29d8, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/her2 primary antibody 29d8/product/Cell Signaling Technology Inc
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    her2 primary antibody 29d8 - by Bioz Stars, 2024-06
    86/100 stars
      Buy from Supplier

    86
    Cell Signaling Technology Inc primary anti her2
    Aptamer selection with cell-SELEX method. A total of 15 selection rounds were applied to enrich DNA aptamer sequences that bind to <t>HER2-overexpressing</t> live breast cancer cell lines SK-BR-3 and MDA-MB-453. MDA-MB-231 cells were used for negative selection.
    Primary Anti Her2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary anti her2/product/Cell Signaling Technology Inc
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    primary anti her2 - by Bioz Stars, 2024-06
    86/100 stars
      Buy from Supplier

    96
    Cell Signaling Technology Inc anti erbb2 monoclonal primary antibody
    Clinicopathological characteristics of HAS and stage-matched non-HAS patients
    Anti Erbb2 Monoclonal Primary Antibody, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti erbb2 monoclonal primary antibody/product/Cell Signaling Technology Inc
    Average 96 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti erbb2 monoclonal primary antibody - by Bioz Stars, 2024-06
    96/100 stars
      Buy from Supplier

    Image Search Results


    Aptamer selection with cell-SELEX method. A total of 15 selection rounds were applied to enrich DNA aptamer sequences that bind to HER2-overexpressing live breast cancer cell lines SK-BR-3 and MDA-MB-453. MDA-MB-231 cells were used for negative selection.

    Journal: Turkish Journal of Biology

    Article Title: Theranostic potential of a novel aptamer specifically targeting HER2 in breast cancer cells

    doi: 10.55730/1300-0152.2680

    Figure Lengend Snippet: Aptamer selection with cell-SELEX method. A total of 15 selection rounds were applied to enrich DNA aptamer sequences that bind to HER2-overexpressing live breast cancer cell lines SK-BR-3 and MDA-MB-453. MDA-MB-231 cells were used for negative selection.

    Article Snippet: For experimentation, primary antibodies against HER2 (2165S), HER3 (12708S), and EGFR (4267S) were obtained from Cell Signaling Technology, while anti-ErbB2 Affibody-Biotin was acquired from Abcam.

    Techniques: Selection

    Expression levels of HER2, HER3, and EGFR on breast cancer cells. Receptor protein levels in MDA-MB-453, SK-BR-3, and MDA-MB-231 cells were detected by on-cell western method using anti-HER2, anti-HER3, and anti-EGFR primary antibodies, then antirabbit 800 (green) conjugated secondary antibody and CellTag 700 (red) stain for normalization of cell number. The plates were scanned in the 800 or 700 nm channels of LI-COR Odyssey Infrared Imaging System.

    Journal: Turkish Journal of Biology

    Article Title: Theranostic potential of a novel aptamer specifically targeting HER2 in breast cancer cells

    doi: 10.55730/1300-0152.2680

    Figure Lengend Snippet: Expression levels of HER2, HER3, and EGFR on breast cancer cells. Receptor protein levels in MDA-MB-453, SK-BR-3, and MDA-MB-231 cells were detected by on-cell western method using anti-HER2, anti-HER3, and anti-EGFR primary antibodies, then antirabbit 800 (green) conjugated secondary antibody and CellTag 700 (red) stain for normalization of cell number. The plates were scanned in the 800 or 700 nm channels of LI-COR Odyssey Infrared Imaging System.

    Article Snippet: For experimentation, primary antibodies against HER2 (2165S), HER3 (12708S), and EGFR (4267S) were obtained from Cell Signaling Technology, while anti-ErbB2 Affibody-Biotin was acquired from Abcam.

    Techniques: Expressing, Western Blot, Staining, Imaging

    Concentration-dependent binding of HMAP7 to HER2 overexpressing breast cancer cells. (A) MDA-MB-453 and SK-BR-3 cells were incubated with increasing concentrations of IRD800-labelled HMAP7 (green) for 1 h. Subsequently, the fluorescence intensities were detected by Infrared Imaging System and used to calculate the dissociation constant Kd value of HMAP7. Anti-HER2 primary and 680RD–labeled (red) secondary antibodies were used to detect HER2 levels. (B) The graph of HMAP7-IRD 800 concentration against fluorescence intensity was plotted. Error bars were calculated as standard error.

    Journal: Turkish Journal of Biology

    Article Title: Theranostic potential of a novel aptamer specifically targeting HER2 in breast cancer cells

    doi: 10.55730/1300-0152.2680

    Figure Lengend Snippet: Concentration-dependent binding of HMAP7 to HER2 overexpressing breast cancer cells. (A) MDA-MB-453 and SK-BR-3 cells were incubated with increasing concentrations of IRD800-labelled HMAP7 (green) for 1 h. Subsequently, the fluorescence intensities were detected by Infrared Imaging System and used to calculate the dissociation constant Kd value of HMAP7. Anti-HER2 primary and 680RD–labeled (red) secondary antibodies were used to detect HER2 levels. (B) The graph of HMAP7-IRD 800 concentration against fluorescence intensity was plotted. Error bars were calculated as standard error.

    Article Snippet: For experimentation, primary antibodies against HER2 (2165S), HER3 (12708S), and EGFR (4267S) were obtained from Cell Signaling Technology, while anti-ErbB2 Affibody-Biotin was acquired from Abcam.

    Techniques: Concentration Assay, Binding Assay, Incubation, Fluorescence, Imaging, Labeling

    The comparison of the receptor-based binding specificities of selected (HMAP7 and M9) and reported (2-2t) aptamers. (A) HER2-overexpressing MDA-MB-453 and SK-BR-3, and HER2-negative MDA-MB-231 cells were incubated with IRD 800-labeled (green) HMAP7, M9 or 2-2t aptamers for 1 h. Subsequently, CellTag 700 (red) applied on-cell western assay. Mean fluorescence intensities were detected by infrared imaging and plotted with standard error as shown (B) .

    Journal: Turkish Journal of Biology

    Article Title: Theranostic potential of a novel aptamer specifically targeting HER2 in breast cancer cells

    doi: 10.55730/1300-0152.2680

    Figure Lengend Snippet: The comparison of the receptor-based binding specificities of selected (HMAP7 and M9) and reported (2-2t) aptamers. (A) HER2-overexpressing MDA-MB-453 and SK-BR-3, and HER2-negative MDA-MB-231 cells were incubated with IRD 800-labeled (green) HMAP7, M9 or 2-2t aptamers for 1 h. Subsequently, CellTag 700 (red) applied on-cell western assay. Mean fluorescence intensities were detected by infrared imaging and plotted with standard error as shown (B) .

    Article Snippet: For experimentation, primary antibodies against HER2 (2165S), HER3 (12708S), and EGFR (4267S) were obtained from Cell Signaling Technology, while anti-ErbB2 Affibody-Biotin was acquired from Abcam.

    Techniques: Comparison, Binding Assay, Incubation, Labeling, Western Blot, Fluorescence, Imaging

    (A) NIR-labeled capture immunoassay for targeted optical imaging. HMAP7-IRD800-treated (green) or IRD800-treated (control) MDA-MB-453 cell lysates were incubated with the streptavidin-coated 96-well plate pretreated with biotinylated anti-HER2-affibody. Then anti-HER2 primary antibody was used and detected with antirabbit 680RD secondary antibody (red) and scanned in the 800 nm and 700 nm channels of LI-COR Odyssey Infrared Imaging System. (B) Schematic diagram of NIR-labeled capture immunoassay.

    Journal: Turkish Journal of Biology

    Article Title: Theranostic potential of a novel aptamer specifically targeting HER2 in breast cancer cells

    doi: 10.55730/1300-0152.2680

    Figure Lengend Snippet: (A) NIR-labeled capture immunoassay for targeted optical imaging. HMAP7-IRD800-treated (green) or IRD800-treated (control) MDA-MB-453 cell lysates were incubated with the streptavidin-coated 96-well plate pretreated with biotinylated anti-HER2-affibody. Then anti-HER2 primary antibody was used and detected with antirabbit 680RD secondary antibody (red) and scanned in the 800 nm and 700 nm channels of LI-COR Odyssey Infrared Imaging System. (B) Schematic diagram of NIR-labeled capture immunoassay.

    Article Snippet: For experimentation, primary antibodies against HER2 (2165S), HER3 (12708S), and EGFR (4267S) were obtained from Cell Signaling Technology, while anti-ErbB2 Affibody-Biotin was acquired from Abcam.

    Techniques: Labeling, Optical Imaging, Incubation, Imaging

    Clinicopathological characteristics of HAS and stage-matched non-HAS patients

    Journal: International Journal of Biological Sciences

    Article Title: Integrative analysis reveals a clinicogenomic landscape associated with liver metastasis and poor prognosis in hepatoid adenocarcinoma of the stomach

    doi: 10.7150/ijbs.71449

    Figure Lengend Snippet: Clinicopathological characteristics of HAS and stage-matched non-HAS patients

    Article Snippet: Following that, the sections were incubated with anti-ERBB2 monoclonal primary antibody (Cell Signaling Technology, #2165), followed by a 30-min incubation with secondary antibody.

    Techniques:

    Potential targets and therapy for HAS. (A) Frequently altered genomic targets in HAS compared with non-HAS. (B) Comparison of ERBB2 expression between HAS and non-HAS. (C) Comparison of TMB between HAS and non-HAS. (D) Assessment of serum AFP and CEA levels in HAS patients before and after treatment. Three HAS patients received anti-ERBB2 therapy and five HAS patients received anti-PD-1 therapy. The line charts represent serum AFP/CEA level and histograms represent the CP of serum AFP/CEA level; details are shown as follows: CP (%) = (serum AFP or CEA levels before treatment - serum AFP or CEA levels after treatment) / serum AFP or CEA levels before treatment *100%. The values of 20 ng/mL and 5 ng/mL are defined as the serum AFP and CEA levels threshold, respectively. For each patient with elevated AFP/CEA level before treatment, 65% was defined as the cutoff for response to anti-ERBB2/anti-PD-1 therapy. Blue and red represent response and no response at the serum tumor biomarker levels, respectively. Grey means that this evaluation criterion is inapplicable for a patient with a normal AFP/CEA level before treatment. (E) Representative CT images of abdomen showing tumor lesions of two patients before and after treatment; one received anti-ERBB2 therapy and the other received anti-PD-1 therapy. The dotted line represents the metastatic liver lesion, and the arrow represents the primary gastric lesion. IHC, immunohistochemistry; AFP, alpha-fetoprotein; CEA, carcinoembryonic antigen; CP, change percent; Pt, patient.

    Journal: International Journal of Biological Sciences

    Article Title: Integrative analysis reveals a clinicogenomic landscape associated with liver metastasis and poor prognosis in hepatoid adenocarcinoma of the stomach

    doi: 10.7150/ijbs.71449

    Figure Lengend Snippet: Potential targets and therapy for HAS. (A) Frequently altered genomic targets in HAS compared with non-HAS. (B) Comparison of ERBB2 expression between HAS and non-HAS. (C) Comparison of TMB between HAS and non-HAS. (D) Assessment of serum AFP and CEA levels in HAS patients before and after treatment. Three HAS patients received anti-ERBB2 therapy and five HAS patients received anti-PD-1 therapy. The line charts represent serum AFP/CEA level and histograms represent the CP of serum AFP/CEA level; details are shown as follows: CP (%) = (serum AFP or CEA levels before treatment - serum AFP or CEA levels after treatment) / serum AFP or CEA levels before treatment *100%. The values of 20 ng/mL and 5 ng/mL are defined as the serum AFP and CEA levels threshold, respectively. For each patient with elevated AFP/CEA level before treatment, 65% was defined as the cutoff for response to anti-ERBB2/anti-PD-1 therapy. Blue and red represent response and no response at the serum tumor biomarker levels, respectively. Grey means that this evaluation criterion is inapplicable for a patient with a normal AFP/CEA level before treatment. (E) Representative CT images of abdomen showing tumor lesions of two patients before and after treatment; one received anti-ERBB2 therapy and the other received anti-PD-1 therapy. The dotted line represents the metastatic liver lesion, and the arrow represents the primary gastric lesion. IHC, immunohistochemistry; AFP, alpha-fetoprotein; CEA, carcinoembryonic antigen; CP, change percent; Pt, patient.

    Article Snippet: Following that, the sections were incubated with anti-ERBB2 monoclonal primary antibody (Cell Signaling Technology, #2165), followed by a 30-min incubation with secondary antibody.

    Techniques: Expressing, Biomarker Assay, Immunohistochemistry